Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above

Condition:   Pneumonia, Pneumococcal Intervention:   Biological: 23-Valent Pneumococcal Polysaccharide Vaccine Sponsor:   Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

ConclusionsCanadian PCV programs have provided significant health benefits and resulted in a substantial value for money. Net savings achieved over the reviewed period would have provided funding for $1.76  billion in other health care costs or public health initiatives. These findings highlight the importance of considering the total value of a vaccination program, rather than vaccine acquisition costs only, when assessing the value of immunization programs.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
Despite vaccination programs, Streptococcus pneumoniae remains among the main microorganisms involved in bacterial pneumonia, notably in terms of severity. The prognosis of pneumococcal infections is conditioned ...
Source: BMC Microbiology - Category: Microbiology Authors: Tags: Research article Source Type: research
ConclusionOld age, immunocompromising conditions and chronic pulmonary/respiratory disease are major risk factors for pneumococcal pneumonia in adults. Our data underline the need for better prevention strategies in these persons.
Source: Lung - Category: Respiratory Medicine Source Type: research
Purpose of review This manuscript reviews the recent literature related to new developments in the understanding of existing and novel virulence factors of the pneumococcus that are of potential importance in the development of novel preventive and therapeutic strategies. Recent findings The pneumococcal capsule and pneumolysin have long been recognized as being two of the most prominent virulence factors, with much recent research having revealed previously unrecognized mechanisms by which they contribute to the pathogenesis of infection. Although the pneumococcal capsule has been considered a sine qua non for virule...
Source: Current Opinion in Pulmonary Medicine - Category: Respiratory Medicine Tags: INFECTIOUS DISEASES: Edited by Michael S. Niederman and Alimuddin Zumla Source Type: research
Pneumococcal disease is characterized by diverse clinical manifestations, but the overall burden is dominated by pneumonia which accounted for 15% of all pediatric deaths in 2017 (World Health Organization, 2019). Furthermore, up to 81% of pneumonia deaths occur in the first two years of life and nearly all pneumonia deaths are recorded in low- and middle-income countries, with Sub-Saharan Africa bearing a great share of pneumonia burden (43% of global pneumonia deaths)(Walker et al., 2013). In 2016, pneumonia was the third most frequent cause of visit to hospital outpatient clinics in Burkina Faso, representing 5 ·...
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
FOSTER CITY, Calif., March 26, 2020 -- (Healthcare Sales &Marketing Network) -- SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious dise... Biopharmaceuticals, Venture Capital SutroVax, conjugate vaccine, vaccine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Adults with chronic conditions such as heart disease, diabetes, or lung disease are more likely to develop complications from a number of vaccine-preventable diseases, including influenza and pneumonia. In thi...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Research article Source Type: research
Corrigendum to "Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE)" [Vaccine 37 (2019) 2687-2693]. Vaccine. 2020 Mar 19;: Authors: Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K PMID: 32201139 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Public health authorities are advising frequent hand washing and social distancing, especially in the absence of confirmatory testing for COVID-19. I don’t have any wisdom to add to these practices. Vaccines are in the works, as are anti-viral drugs—nothing to add here, either. But let me reiterate what we do in the Wheat Belly and Undoctored lifestyles. In general, we do not treat diseases; we correct the factors that allow disease to emerge in the first place—a big difference. Take rheumatoid arthritis, for example. In conventional healthcare, the joint pain and swelling of rheumatoid arthritis are...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Open probiotic undoctored wheat belly Source Type: blogs
Conclusions: Because virtually all cases of pneumococcal meningitis lead to either permanent neurologic sequelae or death, it would be well worth the effort to develop a new vaccine capable of preventing pneumococcal meningitis regardless of capsular type. Such a vaccine would need to protect against colonization with most, if not all, pneumococci.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Commentary Source Type: research
More News: Meningitis Vaccine | Pneomococcal Vaccine | Pneumonia | Research | Vaccines